3 unknown. 3 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 3 | Unknown 3 |
Follow CAR: new trials by email Literature Review of CAR trials Research Report on CAR
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors Chimeric antigen receptor modified γδ T cells - CAR, Malignant Tumors | Early Phase 1 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 8 | 2020-06-03 | 2021-03-08 |
| CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies CD19/CD20 CAR-T cell infusion - CAR | Early Phase 1 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 30 | 2019-04-19 | 2021-03-08 |
| Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. Chimeric antigen receptor T cell - Pancreatic Cancer, CAR | Early Phase 1 | Unknown | First Affiliated Hospital of Harbin Medical University | 10 | 2017-06-15 | 2017-08-30 |
Hematologic Neoplasms (1) · Neoplasms (1) · Pancreatic Neoplasms (1)
Neoplasms (2) · Neoplasms by Site (2) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Pancreatic Diseases (1)
PersonGen BioTherapeutics (Suzhou) Co., Ltd. (2) · First Affiliated Hospital of Harbin Medical University (1)
China (3)
Xingbing Wang (2) · Wei Yunwei, Dctor (1)